496 related articles for article (PubMed ID: 22055591)
21. Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3.
Barreiro P; Martín-Carbonero L; Núñez M; Rivas P; Morente A; Simarro N; Labarga P; González-Lahoz J; Soriano V
Clin Infect Dis; 2006 Apr; 42(7):1032-9. PubMed ID: 16511772
[TBL] [Abstract][Full Text] [Related]
22. Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy.
Chehadeh W; Al-Nakib W
J Med Virol; 2009 Apr; 81(4):610-8. PubMed ID: 19235842
[TBL] [Abstract][Full Text] [Related]
23. Hepatic iron, liver steatosis and viral genotypes in patients with chronic hepatitis C.
Sebastiani G; Vario A; Ferrari A; Pistis R; Noventa F; Alberti A
J Viral Hepat; 2006 Mar; 13(3):199-205. PubMed ID: 16475996
[TBL] [Abstract][Full Text] [Related]
24. Hepatic steatosis and hepatitis C: Still unhappy bedfellows?
Hwang SJ; Lee SD
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():96-101. PubMed ID: 21199519
[TBL] [Abstract][Full Text] [Related]
25. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis.
Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Med Virol; 2005 Apr; 75(4):550-8. PubMed ID: 15714492
[TBL] [Abstract][Full Text] [Related]
26. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity.
Adinolfi LE; Gambardella M; Andreana A; Tripodi MF; Utili R; Ruggiero G
Hepatology; 2001 Jun; 33(6):1358-64. PubMed ID: 11391523
[TBL] [Abstract][Full Text] [Related]
27. Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis.
Gordon A; McLean CA; Pedersen JS; Bailey MJ; Roberts SK
J Hepatol; 2005 Jul; 43(1):38-44. PubMed ID: 15876468
[TBL] [Abstract][Full Text] [Related]
28. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C.
Fartoux L; Chazouillères O; Wendum D; Poupon R; Serfaty L
Hepatology; 2005 Jan; 41(1):82-7. PubMed ID: 15690484
[TBL] [Abstract][Full Text] [Related]
29. Hepatic steatosis and fibrosis in chronic hepatitis C in Taiwan.
Hsieh MH; Lee LP; Hsieh MY; Tsai KB; Huang JF; Hou NJ; Chen SC; Lin ZY; Hsieh MY; Wang LY; Dai CY; Chuang WL; Yu ML
Jpn J Infect Dis; 2007 Nov; 60(6):377-81. PubMed ID: 18032828
[TBL] [Abstract][Full Text] [Related]
30. [Steatosis in chronic viral hepatitis C: frequency, risk factors and relationship with fibrosis].
Karoui S; Taieb Jomni M; Bellil K; Haouet S; Boubaker J; Filali A
Tunis Med; 2008 Jul; 86(7):670-5. PubMed ID: 19472729
[TBL] [Abstract][Full Text] [Related]
31. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
[TBL] [Abstract][Full Text] [Related]
32. [Is APRI score a suitable tool for prediction of fibrosis in Tunisian patients with genotype 1 chronic viral hepatitis C?].
Karoui S; Ben Romdhane S; Serghini M; Ben Mustapha N; Boubaker J; Haouet S; Filali A
Tunis Med; 2012 Apr; 90(4):282-5. PubMed ID: 22535341
[TBL] [Abstract][Full Text] [Related]
33. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.
Bressler BL; Guindi M; Tomlinson G; Heathcote J
Hepatology; 2003 Sep; 38(3):639-44. PubMed ID: 12939590
[TBL] [Abstract][Full Text] [Related]
34. Analysis of histopathological changes that influence liver stiffness in chronic hepatitis C. Results from a cohort of 324 patients.
Lupşor M; Badea R; Stefănescu H; Grigorescu M; Sparchez Z; Serban A; Branda H; Iancu S; Maniu A
J Gastrointestin Liver Dis; 2008 Jun; 17(2):155-63. PubMed ID: 18568136
[TBL] [Abstract][Full Text] [Related]
35. The usefulness of measuring liver stiffness by transient elastography for assessing hepatic fibrosis in patients with various chronic liver diseases.
Tamano M; Kojima K; Akima T; Murohisa T; Hashimoto T; Uetake C; Sugaya T; Nakano M; Hiraishi H; Yoneda M
Hepatogastroenterology; 2012 May; 59(115):826-30. PubMed ID: 22469726
[TBL] [Abstract][Full Text] [Related]
36. [Steatosis in chronic hepatitis C: prevalence and predictive factors].
Ouakaa-Kchaou A; Gargouri D; Kochlef A; Debbiche A; Elloumi H; Ghouma M; Kilani A; Romani M; Kharrat J; Ghorbel A
Tunis Med; 2011 Nov; 89(11):830-6. PubMed ID: 22179918
[TBL] [Abstract][Full Text] [Related]
37. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis.
Gaia S; Carenzi S; Barilli AL; Bugianesi E; Smedile A; Brunello F; Marzano A; Rizzetto M
J Hepatol; 2011 Jan; 54(1):64-71. PubMed ID: 20932598
[TBL] [Abstract][Full Text] [Related]
38. Role of Helicobacter pylori in patients with HCV-related chronic hepatitis and cirrhosis with or without hepatocellular carcinoma: possible association with disease progression.
Esmat G; El-Bendary M; Zakarya S; Ela MA; Zalata K
J Viral Hepat; 2012 Jul; 19(7):473-9. PubMed ID: 22676359
[TBL] [Abstract][Full Text] [Related]
39. Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection.
Petta S; Macaluso FS; Cammà C; Marco VD; Cabibi D; Craxì A
Liver Int; 2012 Oct; 32(9):1443-50. PubMed ID: 22764879
[TBL] [Abstract][Full Text] [Related]
40. High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C.
Petta S; Handberg A; Marchesini G; Cammà C; Di Marco V; Cabibi D; Macaluso FS; Craxì A
J Viral Hepat; 2013 Mar; 20(3):174-82. PubMed ID: 23383656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
